| |
Wednesday, January 15, 2025 | 12pm ET / 9am PT Sort through the noise and hear from Washington Insiders. This session will offer key insights into the economic and political landscape, guiding your company on how best to prepare for and respond to potential changes in funding opportunities and compliance requirements. Register now.
|
|
Today’s Big NewsDec 18, 2024 |
|
Wednesday, January 15, 2025 | 11am ET / 8am PT Discover how next-gen Protein A resins and multi-column chromatography can help biomanufacturers optimize costs, enhance purification efficiency, and improve productivity. Learn practical strategies and explore real-world case studies showcasing advanced solutions for scalable, high-throughput processes. Register now.
|
|
| By Darren Incorvaia Ring Therapeutics, a Flagship Pioneering-backed biotech developing new viral vectors for gene therapy delivery, has cut its staff by just under 50%, a company spokesperson confirmed to Fierce Biotech. |
|
|
|
By James Waldron Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a preclinical drug. |
By Gabrielle Masson Alphabet spinoff SandboxAQ has raised more than $300 million to go toward developing AI applications across multiple areas including drug discovery, chemistry and medical devices. |
By Kevin Dunleavy After the recent release of two independent studies suggested the use of Ozempic increases patients' chances of developing a rare eye disorder, the European Union has decided to investigate the issue, according to a report from Reuters. |
|
Antibody-based therapies have transformed the treatment of many diseases, with biologics remaining at the cutting-edge of R&D today. Access this insightful resource today to explore the traditional technologies used for finding antibody hits, and the latest innovations helping to overcome the top challenges with legacy methods. Download now.
|
|
By Zoey Becker High-dose Eylea demonstrated non-inferiority to the original version of the drug in patients with macular edema following retinal vein occlusion, an indication Eylea has held for a decade. |
By Conor Hale Roche plans to expand its automated testing menu to more than 60 analytes that gauge vitamin D metabolites, immunosuppressant and other therapeutic drug levels. |
By Andrea Park Takeda kicked off 2024 by reeling in an approval for HyQvia in chronic inflammatory demyelinating polyneuropathy, and it’s closing out the year by launching its first direct-to-consumer campaign for the new indication. |
By Gabrielle Masson Freshly public BioAge Labs has secured a multi-year partnership with Novartis that focuses on age-related diseases and includes the possibility of up to $550 million biobucks. |
By Joseph Keenan Indian drugmakers Aurobindo, Glenmark and Zydus have issued separate sweeping drug recalls over issues pertaining to impurities and labeling. The product pulls were catalogued in a recent edition of the FDA's weekly enforcement report. |
By Conor Hale BD and Babson Diagnostics are making their miniaturized approach available to healthcare providers after years of development. |
By Fraiser Kansteiner ACG this week commenced work at its new, 175,000-square-meter capsule production plant in Rayong on Thailand’s east coast. The sprawling facility, which is bigger than 32 football fields, represents the largest of its kind in the country and is expected to crank out some 20 billion hard gelatin capsules per year. |
By Gabrielle Masson SiteOne Therapeutics is powering up with $100 million to advance its early pipeline of non-opioid therapeutics that target the peripheral nervous system instead of the central nervous system. |
By Andrea Park CMI Media Group’s pharmaceutical ads that play via streaming services are about to get a lot smarter. |
By Darren Incorvaia As human cases of avian influenza slowly tick up amid the outbreak in U.S. dairy cattle, the Centers for Disease Control and Prevention and Moderna have teamed up to design an mRNA vaccine for the current variant that successfully protected ferrets from succumbing to the virus. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” we hear from Novo Nordisk CSO Marcus Schindler about his role at the Danish pharma and what’s next for the GLP-1 drug class. |
|
|---|
|
|
|
The European orphan drug market presents a significant opportunity, with forecasts predicting substantial growth in the coming years. Early access programs (EAPs) have emerged as a critical strategy for successfully launching rare disease therapies in this complex and diverse market. Access this whitepaper to learn more.
|
|
| WhitepaperWe interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
